Advanced Proteome Therapeutics Corp (APC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Advanced Proteome Therapeutics Corp (APC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10014
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Advanced Proteome Therapeutics Corporation (APC) is a biopharmaceutical company that focuses on the development of anticancer therapeutics that capitalizes on the properties of a natural human protein. It creates, develops and commercializes novel therapies. The company is advancing a site-specific protein modification technology platform for the development of proprietary human protein pharmaceuticals with enhanced therapeutic properties and greater affinity for the target cancer cells and tumors. The patent pending technology combines anti-cancer therapies in a single agent to directly target cancerous tumors and avoid destroying normal cells. The company carries out its operations through its subsidiary; Advanced Proteome Therapeutics Inc. APC is headquartered in Boston, Massachusetts, the US.

Advanced Proteome Therapeutics Corp (APC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Proteome Therapeutics Corp, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Advanced Proteome Raises USD0.1 Million in Venture Financing 13
Advanced Proteome Raises USD0.2 Million in Venture Financing 14
Advanced Proteome Raises USD0.3 Million in Venture Financing 15
Advanced Proteome Therapeutics Raises US$0.04 Million In Venture Financing 16
Partnerships 17
Advanced Proteome Therapeutics Enters into Collaboration Agreement with Noria Pharma 17
Advanced Proteome Enters into Agreement with ImmunoBiochem 18
Advanced Proteome Therapeutics Expands Agreement with National Research Council of Canada 19
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 20
Licensing Agreements 21
Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 21
Advanced Proteome Therapeutics Enters into Option Agreement with Toronto Recombinant Antibody Centre 22
Equity Offering 23
Advanced Proteome Therapeutics Raises USD0.2 Million in First Tranche Private Placement of Units 23
Advanced Proteome Raises USD0.1 Million in Second Tranche of Private Placement of Units 24
Advanced Proteome Therapeutics to Raise USD0.4 Million in Private Placement of Shares 25
Advanced Proteome Therapeutics Raises USD0.3 Million in Rights Offering of Units 26
Advanced Proteome Therapeutics Raises USD0.1 Million in First Tranche of Private Placement of Units 27
Advanced Proteome Therapeutics to Raise USD0.2 Million in Private Placement of Shares 28
Advanced Proteome Therapeutics Raises USD0.2 Million in Private Placement of Units 29
Advanced Proteome Therapeutics Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 31
Advanced Proteome Therapeutics Raises USD0.6 Million in Private Placement of Units 32
Advanced Proteome Therapeutics Raises USD0.24 Million in Private Placement of Units 33
Advanced Proteome Therapeutics Raises USD0.17 Million in Private Placement of Units 34
Advanced Proteome Therapeutics Completes Private Placement Of Shares For US$0.2 Million 35
Advanced Proteome Therapeutics Completes Private Placement Of Units For US$0.7 Million 36
Advanced Proteome Therapeutics Completes Private Placement Of Units For US$0.3 Million 37
Advanced Proteome Therapeutics Completes First Tranche Of Private Placement Of Units For US$0.2 Million 38
Advanced Proteome Therapeutics Corp – Key Competitors 39
Advanced Proteome Therapeutics Corp – Key Employees 40
Advanced Proteome Therapeutics Corp – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Corporate Communications 42
Jun 06, 2018: Advanced Proteome Therapeutics Names Bill Dickie As Chief Executive Officer, President And Director 42
Apr 24, 2018: Advanced Proteome Therapeutics Announces Appointment of Scientific Advisory Board Members 43
Apr 16, 2018: Advanced Proteome Therapeutics Appoints New Board Members 44
Apr 16, 2018: Advanced Proteome Therapeutics Announces Resignation Of Randal Chase As CEO And Director 45
Jul 31, 2017: Advanced Proteome Therapeutics Announces 2017 AGM Results and Corporate Update 46
Feb 06, 2017: Advanced Proteome Therapeutics Announces the Appointment of Dr. Randal Chase to Its Executive Leadership Team 47
Product News 48
Jun 18, 2018: Advanced Proteome Therapeutics Advances its Technological Capability 48
Other Significant Developments 49
Sep 11, 2018: Advanced Proteome Therapeutics provides overview of current activities and strategic objectives 49
May 01, 2018: Advanced Proteome Therapeutics Updates its Activities During the 3rd Quarter, FY 2018 50
Jan 31, 2018: Advanced Proteome Therapeutics Announces Anti-Cancer R&D Gathers Momentum 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Proteome Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Proteome Therapeutics Corp, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Proteome Raises USD0.1 Million in Venture Financing 13
Advanced Proteome Raises USD0.2 Million in Venture Financing 14
Advanced Proteome Raises USD0.3 Million in Venture Financing 15
Advanced Proteome Therapeutics Raises US$0.04 Million In Venture Financing 16
Advanced Proteome Therapeutics Enters into Collaboration Agreement with Noria Pharma 17
Advanced Proteome Enters into Agreement with ImmunoBiochem 18
Advanced Proteome Therapeutics Expands Agreement with National Research Council of Canada 19
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 20
Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 21
Advanced Proteome Therapeutics Enters into Option Agreement with Toronto Recombinant Antibody Centre 22
Advanced Proteome Therapeutics Raises USD0.2 Million in First Tranche Private Placement of Units 23
Advanced Proteome Raises USD0.1 Million in Second Tranche of Private Placement of Units 24
Advanced Proteome Therapeutics to Raise USD0.4 Million in Private Placement of Shares 25
Advanced Proteome Therapeutics Raises USD0.3 Million in Rights Offering of Units 26
Advanced Proteome Therapeutics Raises USD0.1 Million in First Tranche of Private Placement of Units 27
Advanced Proteome Therapeutics to Raise USD0.2 Million in Private Placement of Shares 28
Advanced Proteome Therapeutics Raises USD0.2 Million in Private Placement of Units 29
Advanced Proteome Therapeutics Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 31
Advanced Proteome Therapeutics Raises USD0.6 Million in Private Placement of Units 32
Advanced Proteome Therapeutics Raises USD0.24 Million in Private Placement of Units 33
Advanced Proteome Therapeutics Raises USD0.17 Million in Private Placement of Units 34
Advanced Proteome Therapeutics Completes Private Placement Of Shares For US$0.2 Million 35
Advanced Proteome Therapeutics Completes Private Placement Of Units For US$0.7 Million 36
Advanced Proteome Therapeutics Completes Private Placement Of Units For US$0.3 Million 37
Advanced Proteome Therapeutics Completes First Tranche Of Private Placement Of Units For US$0.2 Million 38
Advanced Proteome Therapeutics Corp, Key Competitors 39
Advanced Proteome Therapeutics Corp, Key Employees 40
Advanced Proteome Therapeutics Corp, Other Locations 41
Advanced Proteome Therapeutics Corp, Subsidiaries 41

List of Figures
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Proteome Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Proteome Therapeutics Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Advanced Proteome Therapeutics Corp (APC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Caixa Economica Federal:企業の戦略・SWOT・財務情報
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Productos Medix SA de CV:製薬・医療:M&Aディール及び事業提携情報
    Summary Productos Medix SA de CV (Medix), formerly Laboratories Laif is a provider of research, development, manufacturing and marketing of pharmaceutical chemical products. The company’s products comprise livermade, pylopac, imidex, seronex, feprorex, MZ1, redotex, terfamex, prepram,sinestron, anta …
  • TRACON Pharmaceuticals Inc (TCON):企業の財務・戦略的SWOT分析
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product …
  • Eli Lilly and Company:企業のM&A・事業提携・投資動向
    Eli Lilly and Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eli Lilly and Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Qualcomm Incorporated (QCOM)-医療機器分野:企業M&A・提携分析
    Summary Qualcomm Incorporated (Qualcomm) is a technology and communication company. The company designs and manufactures digital wireless telecommunications products and services. Qualcomm offers integrated circuits and system software for wireless mobile devices. The major technologies such as code …
  • Suzlon Energy Ltd (SUZLON):電力:M&Aディール及び事業提携情報
    Summary Suzlon Energy Ltd (Suzlon) is a provider of renewable energy solutions. It offers total solutions package that covers the entire wind energy projects scope. The company provides complete turnkey solutions from design to lifecycle asset management. Suzlon also generates electricity; and sells …
  • Myriad Genetics Inc (MYGN):企業の財務・戦略的SWOT分析
    Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Purdue Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Purdue Pharma Inc (Purdue Pharma Canada), a subsidiary of Purdue Pharma LP is a research-based pharmaceutical company that offers services such as development, manufacturing and commercialization of medicines for patients and healthcare professionals. The company portfolio of products includ …
  • Ossur hf (OSSR):医療機器:M&Aディール及び事業提携情報
    Summary Ossur hf. (Ossur) is an orthopedic devices company. It develops, manufactures and sells prosthetics, and bracing and support products. The company’s key areas of expertise include silicone, carbon composites, mechatronics and textiles. Ossur offers ankle and foot supports, knee braces, neck …
  • Colgate-Palmolive (India) Ltd:企業の戦略・SWOT・財務情報
    Colgate-Palmolive (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary Colgate-Palmolive (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aptiv Plc
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • VQ OrthoCare:企業の戦略的SWOT分析
    VQ OrthoCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hoya Corp (7741):医療機器:M&Aディール及び事業提携情報
    Summary Hoya Corp (Hoya) is a global med-tech company that manufactures and sells precision devices and instruments built on its advanced optics technologies. Principal products include eyeglass and contact lenses, medical endoscopes, laparoscopic surgical instruments, intraocular lenses, orthopedic …
  • HTP Korcula d.d.:企業の戦略・SWOT・財務分析
    HTP Korcula d.d. - Strategy, SWOT and Corporate Finance Report Summary HTP Korcula d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Global Franchise Architects Co.,Ltd.:企業の戦略・SWOT・財務分析
    Global Franchise Architects Co.,Ltd. - Strategy, SWOT and Corporate Finance Report Summary Global Franchise Architects Co.,Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Pearson plc:企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TMX Group Ltd (X):企業の財務・戦略的SWOT分析
    TMX Group Ltd (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Magyar Nemzeti Bank:企業の戦略的SWOT分析
    Magyar Nemzeti Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Merck & Co Inc (MRK):医療機器:M&Aディール及び事業提携情報
    Summary Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune …
  • Unchained Labs-製薬・医療分野:企業M&A・提携分析
    Summary Unchained Labs is a life science tools company which offers protein stability assessment products for biologics. Its product portfolio includes UNcle (biologics stability platform), HUNK (aggregation predictor), pUNk (protein sizing system), GRUNT (automated formulation preparation system), …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆